Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis
- 1 December 2011
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (34), 4510-4515
- https://doi.org/10.1200/jco.2011.35.0991
Abstract
To assess the risk of second primary cancer (SPC) after [125I]iodine prostate cancer brachytherapy compared with prostatectomy and the general population. In a cohort consisting of 1,888 patients with prostate cancer who received monotherapy with brachytherapy (n = 1,187; 63%) or prostatectomy (n = 701; 37%), SPC incidences were retrieved by linkage with the Dutch Cancer Registry. Standardized incidence rates (SIRs) and absolute excess risks (AERs) were calculated for comparison. A total of 223 patients were diagnosed with SPC, 136 (11%) after brachytherapy and 87 (12%) after prostatectomy, with a median follow-up of 7.5 years. The SIR for all malignancies, bladder cancer, and rectal cancer were 0.94 (95% CI, 0.78 to 1.12), 1.69 (95% CI, 0.98 to 2.70), and 0.90 (95% CI, 0.41 to 1.72) for brachytherapy and 1.04 (95% CI, 0.83 to 2.28), 1.82 (95% CI, 0.87 to 3.35), and 1.50 (95% CI, 0.68 to 2.85) for prostatectomy, respectively. Bladder SPC risk was significantly increased after brachytherapy for patients age 60 years or younger (SIR, 5.84; 95% CI, 2.14 to 12.71; AER, 24.03) and in the first 4 years of follow-up (SIR, 2.14; 95% CI, 1.03 to 3.94; AER, 12.24). Adjusted for age, the hazard ratio (brachytherapy v prostatectomy) for all SPCs combined was 0.87 (95% CI, 0.64 to 1.18). Overall, we found no difference in SPC incidence between patients with prostate cancer treated with prostatectomy or brachytherapy. Furthermore, no increased tumor incidence was found compared with the general population. We observed a higher than expected incidence of bladder SPC after brachytherapy in the first 4 years of follow-up, probably resulting from lead time or screening bias. Because of power limitations, a small increased SPC risk cannot be formally excluded.Keywords
This publication has 39 references indexed in Scilit:
- Fifteen-Year Biochemical Relapse-Free Survival, Cause-Specific Survival, and Overall Survival Following I125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle ExperienceInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate CancerJournal of Urology, 2010
- Long-Term Biochemical and Survival Outcome of 921 Patients Treated With I-125 Permanent Prostate BrachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Outcomes Following Iodine-125 Monotherapy for Localized Prostate Cancer: The Results of Leeds 10-Year Single-Center Brachytherapy ExperienceInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Risk of Second Malignancies after Prostate Irradiation?Strahlentherapie und Onkologie, 2007
- Secondary Cancer After Radiotherapy for Prostate Cancer: Should We Be More Aware of the Risk?European Urology, 2007
- Quality of Life Following Treatment for Early Prostate Cancer: Does Low Dose Rate (LDR) Brachytherapy Offer a Better Outcome? A ReviewEuropean Urology, 2004
- Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- The Capture-Recapture Method for Estimation of Cancer Registry Completeness: A Useful Tool?International Journal of Epidemiology, 1994
- Completeness of Cancer Registration in Limburg, the NetherlandsInternational Journal of Epidemiology, 1993